Lung Cancer - Non Small CellMLA-MNSCLCNETNCT06621147
Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine Tumors
An observational study of Lung Cancer - Non Small Cell, run by Hongquan Xing.
Trial summary
This study was based on public use data from the SEER database. The study did not require informed consent from the SEER registered cases, and the authors obtained Limited-Use Data Agreements from SEER. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer - Non Small Cell
- What is being tested?
- Surgery
- Type of treatment
- Surgery or procedure
- How many people
- 1,776 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2000to 31 May 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with metastatic non-small cell neuroendocrine tumors
Who may be able to join
- Pathologic Diagnosis of Non-Small Cell Neuroendocrine Carcinoma
- Known Surgical Information
Who cannot join
- Small cell lung cancer
- Age less than 18 years
About this study
Official title: Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine Tumors: Propensity Score Matching
This study was based on public use data from the SEER database. The study did not require informed consent from the SEER registered cases, and the authors obtained Limited-Use Data Agreements from SEER.
Read the detailed description
This study utilized publicly available data from the SEER (Surveillance, Epidemiology, and End Results) database, which is a comprehensive source of information on cancer statistics in the United States. The authors did not need to obtain informed consent from individuals whose cases are registered in the SEER database because the data is anonymized and is meant for public use. Instead, the authors acquired Limited-Use Data Agreements with SEER, which are legal contracts that allow researchers to access and use specific datasets under certain conditions while ensuring that the privacy of the individuals in the database is maintained. This agreement outlines the terms of data use, ensuring that the researchers adhere to guidelines for the ethical handling of data while still enabling them to conduct their research.
- Conditions
- Lung Cancer - Non Small Cell
- Being tested
- Surgery
- Keywords
- lung cancer, machine learning, non-small cell neuroendocrine tumor
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurgeryProcedure or surgery
Surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Overall survival refers to the duration of time from the start of diagnosis until death from any cause. It is a common endpoint used in clinical trials and medical research, particularly in oncology, to measure the effectiveness of a treatment or intervention. Overall survival provides a comprehensive picture of how well patients are doing and is often expressed as a percentage or a median time (e.g., the median overall survival time).
Measured: The estimated time period for assessing events was January 2000 through December 2021. It is the time from random assignment to death from any cause (last follow-up for lost patients; end of follow-up for patients still alive at the end of the study).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start1 Jan 2000
- Primary completion31 Dec 2021
- Study completion31 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer - Non Small CellStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 1,776 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hongquan Xing
- Sponsor type
- University, hospital or other
- Collaborators
- Second Affiliated Hospital of Nanchang University
- Responsible party
- Sponsor-investigator, Hongquan Xing, Nanchang University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06621147
- Sponsor's protocol ID
- NanchangU
- Acronym
- MLA-MNSCLCNET
- Status last verified
- Sep 2024
- First submitted
- 27 Sep 2024
- Last updated
- 1 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine Tumors: Propensity Score Matching
- ClinicalTrials.gov ID
- NCT06621147
- Acronym / sponsor ID
- MLA-MNSCLCNET / NanchangU
- Conditions
- Lung Cancer - Non Small Cell
- Keywords
- lung cancer, machine learning, non-small cell neuroendocrine tumor
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,776 participants (actual)
- Lead sponsor
- Hongquan XingUniversity, hospital or other
- Collaborators
- Second Affiliated Hospital of Nanchang University
- Study start
- 1 Jan 2000 (actual)
- Primary completion
- 31 Dec 2021 (actual)
- Study completion
- 31 May 2024 (actual)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was based on public use data from the SEER database. The study did not require informed consent from the SEER registered cases, and the authors obtained Limited-Use Data Agreements from SEER.
Detailed description
This study utilized publicly available data from the SEER (Surveillance, Epidemiology, and End Results) database, which is a comprehensive source of information on cancer statistics in the United States. The authors did not need to obtain informed consent from individuals whose cases are registered in the SEER database because the data is anonymized and is meant for public use. Instead, the authors acquired Limited-Use Data Agreements with SEER, which are legal contracts that allow researchers to access and use specific datasets under certain conditions while ensuring that the privacy of the individuals in the database is maintained. This agreement outlines the terms of data use, ensuring that the researchers adhere to guidelines for the ethical handling of data while still enabling them to conduct their research.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with metastatic non-small cell neuroendocrine tumors
Key inclusion criteria (2 listed)
- Pathologic Diagnosis of Non-Small Cell Neuroendocrine Carcinoma
- Known Surgical Information
Key exclusion criteria (2 listed)
- Small cell lung cancer
- Age less than 18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SurgerySurgery | Procedure or surgery | – |
Primary outcome
Overall survival
Time frame: The estimated time period for assessing events was January 2000 through December 2021. It is the time from random assignment to death from any cause (last follow-up for lost patients; end of follow-up for patients still alive at the end of the study).
Overall survival refers to the duration of time from the start of diagnosis until death from any cause. It is a common endpoint used in clinical trials and medical research, particularly in oncology, to measure the effectiveness of a treatment or intervention. Overall survival provides a comprehensive picture of how well patients are doing and is often expressed as a percentage or a median time (e.g., the median overall survival time).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2024.
Related trials for Lung Cancer - Non Small Cell
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 2/3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Non-small Cell Lung Cancer
Recruiting
Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme - A Single-arm Study
Lung Cancer
RecruitingPhase 2
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer - Non Small Cell, run by Hongquan Xing.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: The estimated time period for assessing events was January 2000 through December 2021. It is the time from random assignment to death from any cause (last follow-up for lost patients; end of follow-up for patients still alive at the end of the study).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.